Insights into this mesenchymal-related molecular mechanism may facilitate the development of critically lacking therapeutic options for these devastating malignancies.
The PI3K/AKT signaling pathway is aberrant in a wide variety of cancers. Downstream effectors of AKT are involved in survival, growth and metabolic-related pathways. In contrast, contradictory data relating to AKT effects on cell motility and invasion, crucial prometastatic processes, have been reported pointing to a potential cell type and isoform type-specific AKT-driven function. By implication, study of AKT signaling should optimally be conducted in an appropriate intracellular environment. Prognosis in soft-tissue sarcoma (STS), the aggressive malignancies of mesenchymal origin, is poor, reflecting our modest ability to control metastasis, an effort hampered by lack of insight into molecular mechanisms driving STS progression and dissemination. We examined the impact of the cancer progressionrelevant AKT pathway on the mesenchymal tumor cell internal milieu. We demonstrate that AKT1 activation induces STS cell motility and invasiveness at least partially through a novel interaction with the intermediate filament vimentin (Vim) . The binding of AKT (tail region) to Vim (head region) results in Vim Ser39 phosphorylation enhancing the ability of Vim to induce motility and invasion while protecting Vim from caspase-induced proteolysis. Moreover, vimentin phosphorylation was shown to enhance tumor and metastasis growth in vivo.
Introduction
AKT kinase is a convergence point for multiple extracellular and other upstream signals functioning as a master switch to generate a plethora of intracellular signals and responses. Much evidence exists to support an important role for AKT in human cancer (Sulis and Parsons, 2003) . Downstream effectors of AKT are thought to be involved in survival, growth and metabolic-related pathways (Phung et al., 2006) . In contrast, AKT effects on cell motility and invasion, prerequisite processes for metastasis, although suggested, have been less well elucidated (Grille et al., 2003) . AKT is a family of isoforms including AKT1, AKT2 and AKT3, sharing structural similarities. The expression patterns of the AKT isoforms differ, as do their apparent biological activities (Sumitani et al., 2002) . Although both AKT1 and AKT2 have roles in cell motility and invasion, distinct and even opposing functions have been observed. Several studies demonstrated that AKT1 attenuates invasive migration of breast cancer cells (Irie et al., 2005; Yoeli-Lerner et al., 2005; Liu et al., 2006) , whereas AKT2 promoted migration in these cells in a growth factor-dependent manner (Irie et al., 2005) . Similar findings were seen in vivo in breast and ovarian cancer models (Arboleda et al., 2003; Hutchinson et al., 2004; Maroulakou et al., 2007) . In contrast, a recent study identified AKT1 as inducing the migration of mammary epithelial tumor cells; AKT1 deficiency reduced migration and inhibited metastasis in an ErbB2-induced breast cancer mouse model (Ju et al., 2007) . Both AKT1 and AKT2 were found to enhance the invasiveness of human pancreatic cancer cells (Tanno et al., 2001) . Several potential direct and indirect AKT targets have been identified as participating in regulation of actin cytoskeleton organization, cellular interaction with the extracellular matrix, expression of motility genes and establishment of cellular polarity (Miyazaki et al., 2007) . These studies point to the potential tumor cell-and AKT isoform-type-specific function as relevant to regulation of tumor cell migration/invasion. By implication, study of signaling pathways should optimally be conducted in an appropriate intracellular environment to best understand AKT complex effects.
Mesenchymal-derived soft-tissue sarcomas (STS) are rare compared with epithelial-origin tumors and comprise more than 50 distinct histological subtypes. Genetically, STS are classified into two major subgroups: those with simple karyotypes and specific genetic alterations (translocations or point mutations, for example, gastro intestinal stromal tumor) and a more prevalent cohort that has complex, unbalanced aneuploid karyotypes (for example, leiomyosarcoma). STS disseminate hematogenously, particularly to the lungs; these metastases are a major determinant of the 5-year 50% overall STS survival rate, a survivorship now stagnant for nearly 50 years. Chemotherapy is used to control dissemination, but few drugs have efficacy in STS (Clark et al., 2005) . The lack of effective systemic therapy is thus the major unresolved STS clinical dilemma.
Recent molecular insights have led to new therapy for some simple-karyotype STS. In contrast, the molecular diversity and intricacy of genetically complex STS has impeded a comparable awareness of molecular deregulations driving sarcomagenesis, progression and metastasis needed for therapeutic progress in this latter group. Studies of epithelial cancers indicate that both invasion and metastasis may depend on the acquisition of a mesenchymal phenotype by the incipient cancer cell (Yang and Weinberg, 2008) . Therefore, it is logical to propose that STS, originating from mesenchymal cells, might possess inherent capacities for enhanced migration/invasion. Identifying the molecular basis for these processes could provide a heretofore unexploited basis for development of critically needed therapies for STS.
Although not extensively explored, evidence points to possible involvement of AKT in STS development and progression. Increased pAKT expression in a large panel of complex karyotype STS has recently been reported (Hernando et al., 2007) and a correlation between pAKT expression and subsequent tumor recurrence and patient survival was described (Tomita et al., 2006) . Using a conditional PTEN knockout mouse model, a critical role for AKT in leiomyosarcoma development was shown (Hernando et al., 2007) . We have recently demonstrated a significant impact of AKT inhibition on STS growth in vitro and in vivo (Zhu et al., 2008) . However, little is known about the contributions of AKT to STS migration and invasion, or about possible AKT downstream targets that are affected in the unique mesenchymal STS intracellular milieu. To bridge this knowledge gap, we evaluated the contribution of AKT, specifically the AKT1 isoform, to complex-karyotype STS cell migration and invasion. We identified vimentin (Vim), an intermediate filament highly expressed in mesenchymal cells, as a novel AKT1 downstream target. AKT1 binds to Vim, resulting in Vim phosphorylation and activation, findings of potential significance in establishing novel therapeutics for STS.
Results

AKT1 signaling contributes to STS migration and invasion
The effect of AKT on STS cell migration/invasion was first determined. Activation of AKT (through EGF stimulation) induced a significant increase in migration/ invasion (Po0.05; Figure 1a and Supplementary Figure  S1A ). However, this approach is not specific, in that EGFR stimulation induces multiple downstream signaling pathways. Seeking more specificity, we determined the impact of pAKT blockade on these processes. STS cells were treated for 2 h with the PI3K inhibitor LY294002 (10 mM), the AKT inhibitor A674563 (A563; 1 mM) or with DMSO as a control. After discontinuation of the drugs, viable cells were examined in migration/ invasion assays; a significant decrease was observed (Po0.05; Figure 1a and Supplementary Figure S1A ). In contrast, no significant effect on migration/invasion was observed with an MEK inhibitor (UO126; Supplementary Figures S1A and S1B).
Next, primary cultures of normal smooth muscle cells and of normal human dermal fibroblasts (mesenchymal cells exhibiting minimal constitutive AKT activity, thus enabling the study of the effects of AKT mutants independent of endogenous AKT impact; Supplementary Figure S1C ) were transiently transfected to express wild-type AKT, dominant-negative AKT (AAA) and constitutively active AKT (DD; transfection efficiency was 470%); functional impact was confirmed by pGSK3b ( Figure 1b and Supplementary Figure S1D ). Control (pcDNA3-transfected) cells exhibited only minimal migration/invasion capacity. Overexpression of wild-type AKT induced a minimal increase in cell migration/invasion; AKT-AAA inhibited cell motility/ invasion. In contrast, AKT-DD increased the number of migrating and invading cells approximately five and sixfold, respectively (Po0.001; Figure 1c and Supplementary Figure S1D ). The effects of activated AKT on GSK3b phosphorylation and cell migration/invasion were not sensitive to PI3K or MEK/ERK pharmacological blockade (Figure 1c ).
The expression of AKT isoforms was examined in a panel of human STS cell lines and primary cultures (see Supplementary Figure S2A for primary culture details). We have previously demonstrated that STS express pAKT under serum and serum-free conditions through a multitude of potential upstream mechanisms (Zhu et al., 2008) . Here, we show that STS cells express pAKT (Ser473) and all three AKT isoforms to varying levels ( Figure 2a ); however, only AKT1 was found to be constitutively phosphorylated ( Figure 2b ). Furthermore, EGF stimulation resulted in marked AKT1 phosphorylation ( Figure 2c ); AKT3 phosphorylation was also seen to a lesser extent but there was no evidence of AKT2 phosphorylation. This selective effect was not specific for EGFR activation and was also seen after HGF stimulation (data not shown). In contrast, EGF stimulation induced AKT2 phosphorylation in the epithelial-origin MDA-231 cell line. This differential effect was further confirmed by nonradioactive AKT1 and AKT2 kinase assays ( Figure 2c ). AKT1 knockdown significantly inhibited the migration/invasion of STS cells (Po0.05); no significant comparable effects were observed after AKT2 knockdown (Figure 2d ). Interestingly, forced expression of AKT2 into STS cells does result in its constitutive and inducible phosphorylation (Supplementary Figure S2B ) and is able to rescue the effects of AKT1 knockdown on STS cell migration/ invasion (Supplementary Figure S2C ). Transfection of AKT2-DD into STS cells results in enhanced migration/ Figure S2D ). Together, these data suggest that AKT2 expression as compared with AKT1 is relatively low in STS.
Vim is a novel AKT1 binding partner Next, we sought to identify novel STS-related AKT1 binding proteins. A proteomics-based approach was used; AKT1-coimmunoprecipitated proteins were analyzed by mass spectrometry (MS) to identify putative AKT1 protein binding partners. Several bands from AKT1 immunoprecipitate were selected for further sequencing and 10 proteins were identified (Figure 3a Supplementary Table S1 ). All identifications, carried out primarily by matrix-assisted laser desorption/ionisation-time of flight MS, were validated by sequencing with analysis of tandem mass. Interaction with AKT1 was further confirmed by immunoprecipitation/western blot (WB) Figure 2 AKT1 is constitutively and inducibly activated in STS cells; its inhibition abrogates migration and invasion. (a) STS cell lines and high-grade human STS primary cultures express pAKT (pS473) and all three AKT isoforms to varying levels (WB). (b) IP for AKT1, AKT2 and AKT3 and corresponding WB demonstrate that only AKT1 is constitutively phosphorylated in STS cells. (c) IP of AKT1, 2 and 3 in STS cells after or without treatment with EGF demonstrates induction of AKT1 and AKT3 phosphorylation but not of AKT2. In contrast, EGF stimulation induces the phosphorylation of AKT2 in MDA231 cells. This differential effect was further demonstrated by an AKT kinase assay using GSK-3 fusion protein as a substrate. (d) SKLMS1 cells were transiently transfected with SMARTpool siRNA (20 nM; two different pools were used) targeting AKT1 or AKT2; a target-specific knockdown was observed (WB). siRNA knockdown of AKT1 but not of AKT2 significantly inhibits STS cell migration/invasion (Po0.05). (Graphs represent the average of three repeated experiments ± s.e.m.; asterisk depicts statistically significant effects (Po0.05); pAKT WB in all panels refers to pS473.) See also Supplementary Figure S2 . A full colour version of this figure is available at the Oncogene journal online.
AKT1 phosphorylates and activates vimentin
Q-S Zhu et al for three of the proteins, DDX5, GRP75 and Vim, as well as for the known AKT1 binding partners MDM2 and GSK3b (Figure 3a ). We focused our investigations on Vim being the major intermediate filament in mesenchymal cells. As expected, Vim expression was seen in all evaluated human STS samples, as well as in primary cell cultures and established cell lines ( Figure 3b ). Interaction between AKT1 and Vim was identified in all STS immunoprecipitates tested (Figure 3c ). AKT2-Vim interaction was also identified, although to a lower degree, most probably reflecting low AKT2 expression levels. To demonstrate the interaction of AKT1 and Vim within the context of the intact STS cell, we have used three assays: (1) double immunofluorescence, demonstrating colocalization of endogenous AKT1 and Vim; (2) co-transfection of DsRed-AKT1 and Vim-green fluorescent protein (GFP), demonstrating colocalization of the transfected proteins through live cell microscopy; and (3) protein-fragment complementation assay (RePCA). Protein-protein interaction was demonstrated by positive fluorescent expression evaluated by microscopy and flow cytometry (Supplementary Figure S3A -C). This interaction was further confirmed in an experimental model by overexpressing Vim and AKT1 in cells expressing low (HEK293) or no (MCF7) Vim (see Supplementary Figure S3D&E ). Finally, using an in vitro cosedimentation assay, we found that AKT1 cosediments with the polymerized Vim fraction (Supplementary Figure S3F) .
To identify the potential interacting sites on AKT1 and Vim, GST-fused full-length AKT1 and specific AKT1 domains, as well as full-length Vim and specific Vim domains, were produced (Figure 4a ). GST-AKT1full length was able to pull down Vim from crude STS cell lysates (Figure 4b) . Similarly, GST-AKT1-Cterminal tail domain, but not other domains, resulted in Vim pull down. Similarly, AKT1 was pulled down by Supplementary Table S1 ). Interaction of proteins 5*, Vim, 7*(DDX5) and 8*(GRP75) with AKT1 (band 6*) was further confirmed by AKT1 IP/WB. Interaction of AKT1 with its known partners MDM2 and GSK3b in STS cells is shown as control. (Figure 4c ). However, data obtained from intact cells do not confirm direct AKT-Vim binding, as intermediary proteins might be involved and AKT-Vim coimmunoprecipitation could be a result of their dual interaction with other proteins. To confirm direct AKT-Vim interaction, an in vitro protein binding assay was conducted. GST-Vim proteins, purified as above, were evaluated for binding to a commercially available AKT1 protein. GST-AKT1 proteins were also incubated with recombinant Vim protein. These in vitro protein binding assays confirmed the direct interaction between AKT1 tail domain and Vim head domain ( Figure 4d ).
Vim is a novel AKT1 kinase target Next, we evaluated whether AKT activation results in Vim phosphorylation. We first evaluated protein extracts from primary human STS samples (see Supplementary Figure S4A ); all samples expressed pAKT to varying degrees (Figure 5a ). Protein extracts were This effect was abrogated on treatment with LY294002 but not by rapamycin. siRNA knockdown of AKT1, but to a lesser degree of AKT2, results in decreased Vim phosphorylation (demonstrated by Vim IP/PAS WB). (c) An in vitro AKT1 kinase assay demonstrates the incorporation of [g-32 P]ATP into GST-VIM in the presence of activated AKT1 kinase but not of AKT1 kinase-dead protein (AKT1-AAA). (d) An in vitro AKT1 kinase assay was performed in the presence of cold ATP and two bands corresponding to Vim treated with AKT1 or without AKT1 were subjected to mass spectrometry; shown is the product ion spectra for the 2 þ -charge state of the TYSLGSALRPSTSR Vim peptide (788.39). LC/MS/MS data-dependent acquisition; product ion spectra were searched against the Swissprot database (Swissprot, Pittsburgh, PA, USA) using Mascot ( Supplementary Table S2 ). The 49 Da ( immunoprecipitated for Vim, and a WB for antiphosphorylated AKT substrate (PAS) antibody was conducted. This antibody, raised against an AKT phosphorylation consensus sequence, detects phosphorylated AKT target sites. Vim was recognized by the PAS antibody in all samples to varying degrees (Figure 5a ). Vim immunoprecipitates from STS cells stimulated with EGF, with or without pretreatment with LY294002 or rapamycin (an mTORC1 inhibitor), were subjected to WB using PAS antibody (Figure 5b ). Vim was recognized by the PAS antibody, and Vim phosphorylation increased in a time-dependent manner after AKT activation and decreased after PI3K blockade but not after the inhibition of mTORC1 and S6 kinase. Similarly, double immunofluorescence studies suggested colocalization of Vim and PAS in STS cells. This colocalization was abrogated after short treatment (4 h) with LY294002 (Supplementary Figure S4B ). Furthermore, AKT1 knockdown markedly decreased Vim phosphorylation, whereas AKT2 did not (Figure 5b) . In contrast to STS cells, no constitutive AKT-induced Vim phoshorylation was observed in normal mesenchymal cells (Supplementary Figure  S1E) . However, overexpression of AKT1-DD in normal cells did induce Vim phosphorylation (Supplementary Figure S1F ). Two-dimensional PAGE WB with an antibody to Vim further supported Vim phosphorylation by AKT1 ( Supplementary Figure S4C) . Protein lysate extracted from cells after treatment with LY294002 or A563 exhibited differential migration of Vim on the isoelectric point axis compared with that from untreated cells, suggesting Vim post-translational modification (most likely related to changes in phosphorylation state) induced by AKT inhibition.
To confirm that Vim is potentially a direct AKT substrate, an in vitro AKT kinase assay was conducted. GST-VIM was phosphorylated by activated AKT1 but not by AKT kinase-dead control (Figure 5c ). To dissect out the exact AKT phosphorylation site(s) in Vim, an in vitro kinase assay was conducted using cold ATP. Vim separated on SDS-PAGE after incubation with or without active AKT1 was identified by Coomassie Blue staining. Corresponding bands were isolated, excised and digested into tryptic peptides, which were in turn subjected to three complementary phosphoproteomics MS-based methods: matrix-assisted laser desorption/ionisation-time of flight, liquid chromatography (Bodenstine and Welch, 2008) /MS/MS and multiple reaction monitoring ( Supplementary Table S2 and Figure 5d and Supplementary  Figure S4D-G) . These studies identified Ser39 of Vim as a potential AKT1 phosphorylation target; no other AKT1induced phosphorylation sites were found.
We next mutated the GST-VIM-full length construct at Ser39-and Ser325 (another Motif Scan (http:// scansite.mit.edu/)-predicted AKT phosphorylation site, Supplementary Table S3 ) to create GST-VIM-S39A and GST-VIM-S325A constructs and used corresponding GST fusion proteins in an AKT1 in vitro kinase assay. Constitutively activated AKT1 induced the phosphorylation of GST-VIM and GST-VIM-S325A, but not GST-VIM-S39A (Figure 5e ). Similarly, immunoprecipitaion using an anti-GFP antibody after transfection of STS cells with either VIM-GFP or VIMS39A-GFP constructs showed that Ser39 mutation abrogates AKT1-induced Vim phosphorylation (Figure 5f ).
AKT1-induced STS cell migration and invasion are mediated by Vim
We sought to evaluate the possible functional biological implications of AKT1-Vim interaction and phosphorylation. MTS assays demonstrated that Vim knockdown resulted in a small (22±5%; Figure 6a ) reduction in growth of STS cells within 24 h; markedly more pronounced was the reduction in STS cell migration/ invasion (Po0.01). Next, MCF7 cells (lacking endogenous Vim) were transfected with Vim, AKT1-DD, WTVim, Vim S39A, or both AKT1-DD and WT or S39A-Vim (Figure 6b ); as previously shown (Hendrix et al., 1997) , WT Vim induced an increase in migration/ invasion, whereas mutated Vim S39A or AKT1-DD overexpression alone did not significantly affect these processes. Co-transfection of WT Vim and AKT-DD resulted in marked Vim phosphorylation and a significant (Po0.05) increase in migration/invasion, whereas transfection of the unphosphorylatable mutated Vim S39A, together with AKT-DD, did not enhance these processes. To further evaluate the importance of AKT1-induced Vim Ser39 phosphorylation, MCF7 cells were transfected with WT or S39D-Vim constructs. The phosphomimetic Vim had a more pronounced effect on MCF7 migration/invasion than did WT Vim (Po0.05; Figure 6c ). Figure 6 AKT1-induced STS cell migration and invasion are mediated, at least in part, by Vim. (a) Vim knockdown resulted in a small (15±5%) reduction in SKLMS1 growth, but a marked decrease in migration/invasion (Po0.01). (b) MCF7 cells were transfected with AKT1-DD, Vim, VimS39A individually or in combination. Overexpression of Vim and, to a higher degree, Vim in conjuncture with AKT-DD resulted in the detection of phosphorylated Vim using Vim IP/PAS WB. WT Vim overexpression in MCF7 cells increased migration/invasion, whereas AKT1-DD overexpression alone did not significantly affect these processes. Moreover, cotransfection of AKT1-DD and WT Vim resulted in the most pronounced effect (P&lt;0.05). In contrast, transfection of mutated Vim S39A did not enhance migration/invasion and these processes were not significantly affected by the co-transfection of AKT-DD and Vim S39A. (c) Forced expression of Vim-S39D enhanced the migration/invasion of MCF7 cells as compared with WT Vim (Po0.05). (d) Endogenous Vim was knocked down in STS cells (using anti-Vim morpholino) and cells were then transfected with either pcDNA, WT Vim, Vim-S39A or Vim-S39D (WB). WT Vim and Vim-S39D were capable of at least partially rescuing the migratory and invasive phenotype of Vim knockdown cells (Po0.005), whereas Vim-S39A had only minimal effects (P40.05). (Graphs represent the average of three repeated experiments ± s.e.m.; asterisk depicts statistically significant effects (Po0.05); pAKT WB in all panels refers to pS473). A full colour version of this figure is available at the Oncogene journal online.
Next, a rescue experiment in STS cells was conducted in which endogenous Vim was first knocked down using anti-Vim antisense morpholino oligomers (Figure 6d) ; cells were transfected with either WTVim, Vim-S39A or Vim-S39D. WTVim and Vim-S39D were capable of, at least partially, rescuing the migratory/invasive phenotype of Vim knocked-down cells (Po0.005), whereas Vim-S39A had only minimal effects (P40.05). Finally, SKLMS1 cells stably transfected to overexpress Vim S39D/GFP exhibited significantly larger tumors and a AKT1 phosphorylates and activates vimentin Q-S Zhu et al higher experimental metastasis rate when injected into severe combined immunodeficient mice as compared with Vim S39A/GFP transfected cells ( Supplementary  Table S4 ).
AKT inhibition induces Vim proteolysis
The effect of AKT inhibition on Vim in STS cells was next evaluated. A decrease in the total level of full-length Vim was observed secondary to both, the AKT inhibitor A563 and the PI3K inhibitor LY294002, and was accompanied by an increase in cleaved Vim products and increased activated caspase-3 levels (Figures 7a and b) . In contrast, neither the MEK inhibitor UO126 nor the mTORC1 inhibitor rapamycin affected Vim expression or induced caspase activation in STS cells (Figure 7b ). Previous data suggest that the initial step in Vim proteolysis is its cleavage by caspase 3 Figure 7 AKT inhibition induces caspase-dependent vimentin proteolysis in STS cells. (a) Treatment with A563 resulted in a dosedependent decrease in total Vim and an increase in Vim cleavage products. (b) Similarly, a dose-dependent decrease in full-length Vim and its increased proteolysis, as well as caspase 3 activation, was seen after LY294002 treatment but not with UO126 or rapamycin. (c) Caspase activity blockade using Z-VAD markedly decreased LY294002-induced Vim proteolysis; no such effect was observed using the proteosome inhibitor MG132. (d) Increase in Vim proteolysis and caspase 3 activation was found in protein extracts from HT1080 xenografts treated with A563. (e) SKLMS1 cells after Vim knockdown (using morpholino oligos) were transfected with pcDNA (control), WT or mutated (S39A or S39D) Vim. Treatment with LY294002 resulted in marked proteolysis of WT Vim or S39A-VIM, whereas no cleavage was noted in cells expressing S39D-VIM. (f) LY294002 treatment resulted in the development of granular GFPexpressing aggregates in SKLMS1 cells transfected with GFP-tagged Vim or GFP-tagged S39A-Vim, but not in cells transfected with GFP-tagged S39D-Vim. (pAKT WB in all panels refers to pS473.) See also Supplementary Figure S5 . A full colour version of this figure is available at the Oncogene journal online.
AKT1 phosphorylates and activates vimentin
Q-S Zhu et al (Byun et al., 2001) . Caspase activity blockade using Z-VAD but not the proteosome inhibitor MG132 significantly decreased LY294002-induced Vim proteolysis (Figure 7c ). Use of frozen tissues from our previously published animal experiments (Zhu et al., 2008) , in which HT1080 xenografts were treated with A563, demonstrated that AKT inhibition-induced Vim proteolysis and caspase 3 activation occur in vivo as well (Figure 7d ). The possible role of Ser39 phosphorylation in protecting Vim from proteolysis was evaluated. Anti-Vim morpholino oligos were used to knock down native Vim, and WT or mutated (S39A or S39D) Vim was forcefully reexpressed. Treatment with LY294002 resulted in marked proteolysis of WT Vim or S39A-Vim, whereas no cleavage was noted in cells expressing S39D-Vim (Figure 7e) . Similarly, LY294002 treatment resulted in the development of granular GFP-expressing aggregates in cells transfected with GFP-tagged WT Vim or GFP-tagged S39A-Vim, but to a markedly lesser degree in cells transfected with GFP-tagged S39D-Vim (Figure 7f and Supplementary Figure S5 ).
Discussion
Our studies identified that AKT1 is constitutively active in STS cells. Moreover, cytokine stimulation induces AKT1 and AKT3 phosphorylation to varying degrees, but not AKT2. The specific mechanisms resulting in this observed differential isoform activation are not known; results here suggest that this may be the consequence of low AKT2 expression levels in STS cells. Other factors such as subcellular localization, differential compartmentalization, selectivity of upstream kinases or phosphatases and perhaps association with unique scaffold proteins or binding partners affecting their accessibility to their upstream effectors might also have an effect. Although not extensively studied in cells of mesenchymal origin, there is some evidence to support the contention that AKT1 enhances migration and invasion. For example, AKT1 was found to promote migration and invasion of fibroblasts and endothelial cells (Kanda et al., 2004; Ackah et al., 2005) . One study evaluated the effect of AKT1 activation on sarcoma cells; overexpression of constitutively active membrane-targeted AKT1 or kinase-dead AKT1 mutants in human fibrosarcoma cells demonstrated that AKT1 enhances motility and invasion, possibly by regulating the expression of matrix metallopeptidase 9 (Kim et al., 2009) . Our results using a knockdown approach substantiate and expand this initial observation; taken together, it is possible to conclude that activation of AKT1 (but not AKT2) enhances STS tumor cell motility and invasion. AKT inhibitors are in various development stages; several pan AKT blockers already being evaluated in human clinical trials. Efforts are under way to develop isoform-specific inhibitors to decrease off-target effects and hopefully reduce drugrelated toxicity. On the basis of the results presented here, AKT1 is a particularly attractive candidate for STS therapy.
The observed dependence of AKT function on cancer type, cell type and AKT isoform can potentially be attributed to unique downstream substrates expressed in a particular intracellular microenvironment. Here, we identified Vim as a potential AKT downstream target in STS. Vim is one of the most widely expressed mammalian intermediate filament proteins. In adults, Vim is present in all mesenchymal cells and tissues (Broers et al., 1989) and is therefore frequently used as a differentiation marker. Insights from genetically engineered Vim knockout mice suggest that the physiological structural role of Vim in quiescent mesenchymal cells is potentially redundant and can be carried out by different cell components; Vim knockout mice are viable and do not exhibit overt phenotypes (Colucci-Guyon et al., 1994) . This observation is an important consideration if Vim is to be further investigated as a therapeutic target. However, several lines of investigation suggest that Vim has functions that extend beyond simple mechanical and structural roles, including involvement in adhesion, migration and cell survival (Hendrix et al., 1997; Eckes et al., 1998; Menet et al., 2001; McInroy and Maatta, 2007; Bhattacharya et al., 2009) . 'Hijacking' of normal physiological processes is a hallmark of cancer; a multitude of potential Vim functions raise the possibility that it could contribute to the protumorigenic, prometastatic properties of STS cells. Although the exact mechanisms underlying Vim function and its activation are mostly unknown, a variety of studies suggest that Vim phosphorylation is a key regulator of these effects. Phosphorylation has a major role in regulating Vim structure, dynamic assembly and interaction with many intracellular structures (including mitochondria and nuclei) and individual proteins (Pittenger et al., 2008) . Vim contains a highly complex phosphorylation pattern involving a multitude of kinase-specific sites (Nelson and Traub, 1983) and is recognized as a substrate for several kinases, including RhoA kinase (Sin et al., 1998) , protein kinase C, cGMP kinase, Yes, Raf-1, PAK and Aurora B (Goto et al., 1998) . For example, protein kinase Ce-mediated Vim phosphorylation at N-terminal residues was found to induce cell motility through integrin recycling and trafficking to the cell membrane (Ivaska et al., 2005) . To our knowledge, the studies presented here are the first to demonstrate an association between AKT and Vim. Furthermore, direct AKTinduced phosphorylation of Vim at Ser39 was identified; alanine mutation of Ser39 perturbed the ability of Vim to induce migration and invasion, whereas expression of mutant Vim with an acidic residue replacing Ser39 enhanced Vim function both in vitro and in vivo. It is of note that the AKT motif found in Vim is RXXS/T and not the classical RXRXXS/T AKT consensus site; this motif has been identified in a large panel of potential AKT substrates (see Supplementary Table S3 ) (Gu et al., 2006; Qi et al., 2006; Fang et al., 2007; Luo et al., 2007) . Being a nonclassical AKT phosphorylation motif, we cannot rule out that the observed AKT-induced AKT1 phosphorylates and activates vimentin Q-S Zhu et al phosphorylation of Vim in STS cells of functional consequences is not a result of an indirect effect due to AKT activation of AGC kinases that are possibly recruited to Vim secondary to AKT:Vim binding and in turn phosphorylate Vim. Irrespective of the case, taken together, our findings identify a novel mechanism of AKT function relevant to STS cells and add an additional downstream target to those with which AKT interacts.
AKT is known for its prosurvival effects; AKT blockade results in significant apoptosis in a multitude of cancer models, including STS (Zhu et al., 2008) . Data presented here offer a potential novel mechanism for AKT blockade-induced apoptosis affecting Vim-expressing cells. A role for Vim in apoptosis was recently elucidated (Byun et al., 2001) . Vim undergoes rapid proteolysis on diverse proapoptotic stimuli, including ionizing radiation, Fas, TRAIL, tumor necrosis factor-a and tamoxifen. This Vim proteolysis occurs secondary to caspase pathway activation, resulting in cleavage of Vim by multiple caspases at several sites (Asp85, Asp259 and Asp429; (Byun et al., 2001) . It is possible that Vim proteolysis and collapse contribute to many of the morphological manifestations of apoptosis, including cellular rounding, nuclear condensation and packaging of the debris of dying cells into apoptotic bodies. Furthermore, Vim proteolysis releases potential proapoptotic proteolytic fragments that can markedly enhance apoptosis. For example, the generation of a short N-terminal cleavage product (amino acids 1-85) was shown to have an active proapoptotic role (Morishima, 1999) . A positive feedback loop is suggested, whereby activated caspases induce the cleavage of Vim and these cleavage products in turn activate caspases to amplify apoptosis. To our knowledge, AKT blockade-induced Vim proteolysis has not been previously described. AKT inhibition is known to induce the activation of caspases; our results elucidate the mechanism by demonstrating that AKT blockade induces caspase-dependent Vim proteolysis in vitro and in vivo. Our results also suggest that AKT-induced Vim phosphorylation protects Vim (to some extent) from caspase proteolysis, suggesting a potential prosurvival effect of AKT. Future clinical trials evaluating the effect of AKT inhibitors on STS could assess the utility of measuring Vim cleavage as a marker of apoptosis/ therapeutic efficacy.
In summary, many key regulatory roles of AKT in STS cells could be at least partially mediated through its interaction with and consequential phosphorylation of Vim. Vim could therefore potentially be selectively targeted for STS therapy. This previously unexplored biology has important therapeutic implications and merits further investigation.
Materials and methods
Cell lines and reagents
A list of cell lines, human cell strains (including isolation and characterization) and culture conditions is provided in the Supplementary Experimental Procedures. A comprehensive list of all commercial antibodies, inhibitors, cytokines, constructs and transfection procedures is described in detail in Supplementary Data.
Cell growth
Cell growth assays were performed with a CellTiter96 Aqueous Non-Radioactive Cell Proliferation Assay kit (Promega, Madison, WI, USA) as per the manufacturer's instructions. Absorbance was measured at 490 nm; absorbance of treated cells is graphically presented as a percentage of control cell absorbance.
Migration and invasion assays
Migration and invasion assays were conducted as described previously (Liu et al., 2006) ; further details are provided in Supplementary Data.
WB and coimmunoprecipitation WB analysis, coimmunoprecipitation and two-dimensional PAGE WB analysis were performed by standard methods. Brief details are provided in Supplementary Data.
MS
In-Gel Trypsin Digestion methodology is described in Supplementary Data. Matrix-assisted laser desorption/ionisation-time of flight MS was used for protein identification of AKT1 binding partners (details are provided in Supplementary Data). Three complementary MS-based methods were used for phosphoproteomics: matrix-assisted laser desorption/ionisation-time of flight, liquid chromatography (Bodenstine and Welch, 2008) /MS/MS and multiple reaction monitoring. Further details can be found in Supplementray Data.
GST fusion protein pull-down and in vitro protein binding assays Expression of GST and GST-tagged full-length Vim, Vim fragments, full-length AKT1 and AKT1 fragments was induced in Escherichia coli BL21, and proteins were purified by immobilization on glutathione-Sepharose-4B beads (GE Healthcare, Piscataway, NJ, USA). Further details are provided in Supplementary Data. For GST fusion protein pulldown assays, 50 ml of beads (5 mg of immobilized protein) were incubated with 500-1000 mg of whole-cell lysates in 1% NP-40 buffer for 4 h at 4 1C. For in vitro protein binding assays, 10 ml of beads (1 mg of immobilized protein) were incubated with commercially available recombinant human Vim (1 mg) or AKT1 (1 mg) in a 1% NP-40 buffer for 2 h at 4 1C. Beads were spun down and washed with cold 1% NP-40 in 1 Â phosphatebuffered saline (1 ml each), boiled in 10 ml of 4 Â SDS gel loading buffer and subjected to SDS-PAGE, followed by WB.
Non-radioactive AKT kinase assay and in vitro AKT kinase assay Non-radioactive Akt Kinase Assay Kit providing all the reagents necessary to measure AKT1 or 2 kinase activity was purchased from Cell Signaling (Danvers, MA, USA). Immobilized AKT antibodies were used to immunoprecipitate AKT1 or w from cell extracts. Thereafter, a kinase assay was performed using GSK-3 fusion protein as a substrate in the presence of 200 mM of cold ATP. Phosphorylation of GSK-3 was measured by WB, using pGSK-3 Ab.
Constitutively activated AKT1 or kinase-dead AKT was incubated with 10 ml of GST affinity matrix bead-purified wildtype or mutated Vim proteins (details provided in the Supplementary Experimental Procedures) in the presence of 5 mCi of [g-32 P]ATP, 50 mM cold ATP and 1.5 Â AKT1 kinase buffer (75 mM Tris (pH 7.4), 25 mM MgCl 2 , 2 mM dithiothreitol, 0.1 mM NaVO 3 , 1.5mM proteinase inhibitor and 1.5 mg/ml bovine serum albumin) for 30 min at room temperature. The reaction mixture was spun down, and the beads were washed with phosphate-buffered saline. After the addition of 10 ml of 4 Â SDS gel loading buffer, reaction products were resolved by SDS-PAGE and g-32 P-labeled proteins were visualized by autoradiography. The experiment was repeated excluding [g-32 P]ATP (only cold ATP was added) for submission of Vim to phosphoprotein MS analysis. Bands were identified by Coomassie Blue staining.
Animal experiments
All animal procedures and care were approved by the Institutional Animal Care and Usage Committee of UTM-DACC and are described in Supplementary Data.
Statistical analysis
All experiments were repeated at least three times to ensure reproducibility. Cell proliferation, migration and invasion assays were repeated three times, and means±s.d. was calculated. Two sample t-tests were used to assess the differences. Significance was set at Pp0.05. Statistical considerations relating to MS studies are described in the Supplementary Data section. Differences in xenograft growth in vivo were assessed using a two-tailed Student's t-test. Significance was set at Pp0.05. All computations were performed with SAS 9.1 (SAS Institute, Cary, NC, USA) and S-PLUS 7.0 (Insightful, Ottawa, ON, Canada).
